Author: admin

The Sensorineural Hearing Loss market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Sensorineural Hearing Loss pipeline products will significantly revolutionize the Sensorineural Hearing Loss market dynamics.

DelveInsight’s “Sensorineural Hearing Loss Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Sensorineural Hearing Loss, historical and forecasted epidemiology as well as the Sensorineural Hearing Loss market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Sensorineural Hearing Loss market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Sensorineural Hearing Loss market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Sensorineural Hearing Loss Market Forecast

Some of the key facts of the Sensorineural Hearing Loss Market Report:

• The Sensorineural Hearing Loss market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

• In May 2025, Envoy Medical®, Inc. (NASDAQ: COCH) (“Envoy Medical”), an innovative hearing health company specializing in fully implanted hearing devices that utilize the ear’s natural structure, today announced reaching a significant milestone with the successful activation of the fully implanted Acclaim® cochlear implants in all 10 participants during the initial phase of the Company’s pivotal clinical trial.

• In February 2025, SPI-1005 was an experimental drug that contained ebselen, a unique seleno-organic compound. Ebselen works by imitating and enhancing the activity of glutathione peroxidase (GPx), an enzyme crucial for reducing neuroinflammation in both the central and peripheral nervous systems. GPx plays an essential protective role across various organs such as the inner ear, retina, prefrontal cortex of the brain, lungs, and kidneys. However, its function often diminishes with age or due to environmental exposure. Studies using different animal models have shown a correlation between reduced GPx activity and the onset of sensorineural hearing loss.

• In August 2024, Sound Pharmaceuticals completed the Phase III clinical trial of SPI-1005, an experimental anti-inflammatory treatment designed for Meniere’s disease. The study, known as STOPMD-3, is touted as the longest treatment trial for hearing loss or tinnitus indications. Initially, participants were enrolled in a randomized controlled trial (RCT) for three months, after which they entered an open-label extension (OLE) for six months (OLE 6-mo), with the option for an additional six months (OLE 12-mo).

• Sensorineural hearing loss (SNHL) is caused by damage to the structures in the inner ear or auditory nerve. It is the cause of more than 90% of hearing loss in adults

• According to Evan Starkman (2022), the most common type tied to Rheumatoid Arthritis (RA) is sensorineural hearing loss, which affects about 25% to 75% of people with RA

• According to Chau et al., a defined cause can be identified for 7% to 45% of patients with Sensorineural Hearing Loss

• Key Sensorineural Hearing Loss Companies: Otonomy, Audion Therapeutics, Frequency Therapeutics, and others

• Key Sensorineural Hearing Loss Therapies: OTO-413, LY3056480, FX-322, and others

• The Sensorineural Hearing Loss market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Sensorineural Hearing Loss pipeline products will significantly revolutionize the Sensorineural Hearing Loss market dynamics.

Sensorineural Hearing Loss Overview

Sensorineural hearing loss (SNHL) is caused by damage to the structures in the inner ear or damage to the auditory nerve. It is the cause of more than 90% of hearing loss in adults. Common causes of SNHL include exposure to loud noises, genetic factors, or the natural aging process.

Get a Free sample for the Sensorineural Hearing Loss Market Report-

https://www.delveinsight.com/report-store/sensorineural-hearing-loss-market

Sensorineural Hearing Loss Market

The dynamics of the Sensorineural Hearing Loss market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.

“Sensorineural Hearing Loss (SNHL), though not a fatal condition, affects one’s Quality of Life considerably; even mild levels of hearing loss can increase the long-term risk of cognitive decline and dementia. Nevertheless, there are no approved drugs on the market for acute hearing loss. Medical fraternity is in urgent need of a treatment with a proven efficacy and safety profile to treat their patients”

Sensorineural Hearing Loss Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Sensorineural Hearing Loss Epidemiology Segmentation:

The Sensorineural Hearing Loss market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Sensorineural Hearing Loss

• Prevalent Cases of Sensorineural Hearing Loss by severity

• Gender-specific Prevalence of Sensorineural Hearing Loss

• Diagnosed Cases of Episodic and Chronic Sensorineural Hearing Loss

Download the report to understand which factors are driving Sensorineural Hearing Loss epidemiology trends @ Sensorineural Hearing Loss Epidemiological Insights

Sensorineural Hearing Loss Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Sensorineural Hearing Loss market or expected to get launched during the study period. The analysis covers Sensorineural Hearing Loss market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Sensorineural Hearing Loss Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Sensorineural Hearing Loss Therapies and Key Companies

• Otonomy: OTO-413

• LY3056480: Audion Therapeutics

• FX-322: Frequency Therapeutics

To know more about Sensorineural Hearing Loss treatment, visit @ Sensorineural Hearing Loss Medications

Sensorineural Hearing Loss Market Drivers

• Increasing Aging Population

• Advancements in Hearing Aid Technology

• Growing Awareness

• Technological Innovations

• Government Initiatives

Sensorineural Hearing Loss Market Barriers

• High Cost of Treatment

• Limited Reimbursement Policies

• Stigma and Awareness

• Complexity in Diagnosis

• Regulatory Challenges

Scope of the Sensorineural Hearing Loss Market Report

• Study Period: 2019–2032

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Sensorineural Hearing Loss Companies: Otonomy, Audion Therapeutics, Frequency Therapeutics, and others

• Key Sensorineural Hearing Loss Therapies: Otonomy, LY3056480, FX-322, and others

• Sensorineural Hearing Loss Therapeutic Assessment: Sensorineural Hearing Loss current marketed and Sensorineural Hearing Loss emerging therapies

• Sensorineural Hearing Loss Market Dynamics: Sensorineural Hearing Loss market drivers and Sensorineural Hearing Loss market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Sensorineural Hearing Loss Unmet Needs, KOL’s views, Analyst’s views, Sensorineural Hearing Loss Market Access and Reimbursement

Discover more about therapies set to grab major Sensorineural Hearing Loss market share @ Sensorineural Hearing Loss Treatment Landscape

Table of Contents

1. Sensorineural Hearing Loss Market Report Introduction

2. Executive Summary for Sensorineural Hearing Loss

3. SWOT analysis of Sensorineural Hearing Loss

4. Sensorineural Hearing Loss Patient Share (%) Overview at a Glance

5. Sensorineural Hearing Loss Market Overview at a Glance

6. Sensorineural Hearing Loss Disease Background and Overview

7. Sensorineural Hearing Loss Epidemiology and Patient Population

8. Country-Specific Patient Population of Sensorineural Hearing Loss

9. Sensorineural Hearing Loss Current Treatment and Medical Practices

10. Sensorineural Hearing Loss Unmet Needs

11. Sensorineural Hearing Loss Emerging Therapies

12. Sensorineural Hearing Loss Market Outlook

13. Country-Wise Sensorineural Hearing Loss Market Analysis (2019–2032)

14. Sensorineural Hearing Loss Market Access and Reimbursement of Therapies

15. Sensorineural Hearing Loss Market Drivers

16. Sensorineural Hearing Loss Market Barriers

17. Sensorineural Hearing Loss Appendix

18. Sensorineural Hearing Loss Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Sensorineural Hearing Loss Market Set to Grow Substantially Through 2032, DelveInsight Projects | Audion Therapeutics, Frequency Therapeutics

DelveInsight’s “Progressive Multifocal Leukoencephalopathy Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Progressive Multifocal Leukoencephalopathy, historical and forecasted epidemiology as well as the Progressive Multifocal Leukoencephalopathy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Progressive Multifocal Leukoencephalopathy, offering comprehensive insights into the Progressive Multifocal Leukoencephalopathy revenue trends, prevalence, and treatment landscape. The report delves into key Progressive Multifocal Leukoencephalopathy statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Progressive Multifocal Leukoencephalopathy therapies. Additionally, we cover the landscape of Progressive Multifocal Leukoencephalopathy clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Progressive Multifocal Leukoencephalopathy treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Progressive Multifocal Leukoencephalopathy space.

To Know in detail about the Progressive Multifocal Leukoencephalopathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Progressive Multifocal Leukoencephalopathy Market Forecast

Some of the key facts of the Progressive Multifocal Leukoencephalopathy Market Report:

• The Progressive Multifocal Leukoencephalopathy market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

• In May 2025, TG Therapeutics, Inc. (NASDAQ: TGTX) has announced its Q1 2025 financial results, recent corporate developments, and updated its revenue guidance for the year. Notably, the company shared five-year data from the open-label extension of the ULTIMATE I & II Phase 3 trials assessing BRIUMVI in adults with relapsing forms of multiple sclerosis (RMS). The results showed that 92% of patients experienced no disability progression after five years, with an exceptionally low annualized relapse rate of 0.02 in year five—equivalent to one relapse per 50 patient-years. BRIUMVI maintained a consistent safety profile with no new safety concerns and no reported cases of progressive multifocal leukoencephalopathy (PML) throughout the five-year treatment period.

• Key Progressive Multifocal Leukoencephalopathy Companies: French National Agency, SmithKline Beecham, NIAID, and others

• Key Progressive Multifocal Leukoencephalopathy Therapies: Enfuvirtide, Topotecan, Filgrastim, and others

• The Progressive Multifocal Leukoencephalopathy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Progressive Multifocal Leukoencephalopathy pipeline products will significantly revolutionize the Progressive Multifocal Leukoencephalopathy market dynamics

• As per DelveInsight’s epidemiological analysis, the United States recorded around 1,687 new cases of Progressive Multifocal Leukoencephalopathy in 2023. This figure is expected to grow throughout the forecast period (2024–2034), primarily due to advancements in diagnostic methods and an increasing aging population.

• In 2023, Germany reported the highest number of new Progressive Multifocal Leukoencephalopathy cases among the EU4 and the UK, with around 420 cases. France followed with approximately 342 cases, while the UK recorded nearly 339 incident cases.

• In the United States in 2023, age-specific data showed that the highest number of new Progressive Multifocal Leukoencephalopathy cases occurred in individuals aged 61–70 years, totaling around 439 cases. In contrast, the lowest incidence was seen in the 20–30 years age group, with approximately 118 cases.

• In 2023, Japan reported around 617 new cases of Progressive Multifocal Leukoencephalopathy among the 7MM countries, with projections indicating potential changes throughout the forecast period.

Progressive Multifocal Leukoencephalopathy Overview

Progressive Multifocal Leukoencephalopathy (PML) is a rare, life-threatening brain infection caused by the John Cunningham virus (JC virus). It occurs primarily in individuals with weakened immune systems, such as those with HIV/AIDS, cancer, or on immunosuppressive therapies. PML leads to the progressive damage (demyelination) of white matter in the brain, affecting nerve cell communication. Symptoms can include vision problems, weakness, cognitive decline, and coordination issues. There is no specific cure for PML; treatment focuses on restoring immune function to control the virus.

Get a Free sample for the Progressive Multifocal Leukoencephalopathy Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/progressive-multifocal-leukoencephalopathy-market

Progressive Multifocal Leukoencephalopathy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Progressive Multifocal Leukoencephalopathy Epidemiology Segmentation:

The Progressive Multifocal Leukoencephalopathy market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Progressive Multifocal Leukoencephalopathy

• Prevalent Cases of Progressive Multifocal Leukoencephalopathy by severity

• Gender-specific Prevalence of Progressive Multifocal Leukoencephalopathy

• Diagnosed Cases of Episodic and Chronic Progressive Multifocal Leukoencephalopathy

Download the report to understand which factors are driving Progressive Multifocal Leukoencephalopathy epidemiology trends @ Progressive Multifocal Leukoencephalopathy Epidemiology Forecast

Progressive Multifocal Leukoencephalopathy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Progressive Multifocal Leukoencephalopathy market or expected to get launched during the study period. The analysis covers Progressive Multifocal Leukoencephalopathy market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Progressive Multifocal Leukoencephalopathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Progressive Multifocal Leukoencephalopathy Therapies and Key Companies

• Enfuvirtide: French National Agency

• Topotecan: SmithKline Beecham

• Filgrastim: NIAID

Discover more about therapies set to grab major Progressive Multifocal Leukoencephalopathy market share @ Progressive Multifocal Leukoencephalopathy Treatment Landscape

Progressive Multifocal Leukoencephalopathy Market Drivers

• Rising Incidence of Immunosuppressive Conditions

• Advancements in Molecular Diagnostics

• Increased Awareness Among Healthcare Providers

• Ongoing Research & Clinical Trials

• Collaborations and Funding Support

Progressive Multifocal Leukoencephalopathy Market Barriers

• Lack of Specific Curative Therapies

• Delayed Diagnosis

• High Treatment Costs

• Low Disease Awareness in General Population

• Challenges in Clinical Trial Recruitment

Scope of the Progressive Multifocal Leukoencephalopathy Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Progressive Multifocal Leukoencephalopathy Companies: French National Agency, SmithKline Beecham, NIAID, and others

• Key Progressive Multifocal Leukoencephalopathy Therapies: Enfuvirtide, Topotecan, Filgrastim, and others

• Progressive Multifocal Leukoencephalopathy Therapeutic Assessment: Progressive Multifocal Leukoencephalopathy current marketed and Progressive Multifocal Leukoencephalopathy emerging therapies

• Progressive Multifocal Leukoencephalopathy Market Dynamics: Progressive Multifocal Leukoencephalopathy market drivers and Progressive Multifocal Leukoencephalopathy market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Progressive Multifocal Leukoencephalopathy Unmet Needs, KOL’s views, Analyst’s views, Progressive Multifocal Leukoencephalopathy Market Access and Reimbursement

To know more about Progressive Multifocal Leukoencephalopathy companies working in the treatment market, visit @ Progressive Multifocal Leukoencephalopathy Clinical Trials and Therapeutic Assessment

Table of Contents

1. Progressive Multifocal Leukoencephalopathy Market Report Introduction

2. Executive Summary for Progressive Multifocal Leukoencephalopathy

3. SWOT analysis of Progressive Multifocal Leukoencephalopathy

4. Progressive Multifocal Leukoencephalopathy Patient Share (%) Overview at a Glance

5. Progressive Multifocal Leukoencephalopathy Market Overview at a Glance

6. Progressive Multifocal Leukoencephalopathy Disease Background and Overview

7. Progressive Multifocal Leukoencephalopathy Epidemiology and Patient Population

8. Country-Specific Patient Population of Progressive Multifocal Leukoencephalopathy

9. Progressive Multifocal Leukoencephalopathy Current Treatment and Medical Practices

10. Progressive Multifocal Leukoencephalopathy Unmet Needs

11. Progressive Multifocal Leukoencephalopathy Emerging Therapies

12. Progressive Multifocal Leukoencephalopathy Market Outlook

13. Country-Wise Progressive Multifocal Leukoencephalopathy Market Analysis (2020–2034)

14. Progressive Multifocal Leukoencephalopathy Market Access and Reimbursement of Therapies

15. Progressive Multifocal Leukoencephalopathy Market Drivers

16. Progressive Multifocal Leukoencephalopathy Market Barriers

17. Progressive Multifocal Leukoencephalopathy Appendix

18. Progressive Multifocal Leukoencephalopathy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Progressive Multifocal Leukoencephalopathy Market Statistics Expected to Experience Major Growth by 2034, According to DelveInsight | French National Agency, SmithKline Beecham, NIAID

According to DelveInsight’s analysis, The dental implants and prosthesis market is witnessing significant growth, largely driven by the increasing prevalence of oral health problems, periodontal diseases, and dental conditions. Additionally, the growing elderly population—more susceptible to dental issues—is contributing to the heightened need for dental care and related products. These factors are expected to play a major role in propelling the market’s expansion from 2024 to 2030.

DelveInsight’s “Dental Implants And Prosthesis Market Insights, Competitive Landscape and Market Forecast-2030” report provides the current and forecast market outlook, forthcoming device innovation, challenges, market drivers and barriers. The report also covers the major emerging products and key Dental Implants And Prosthesis companies actively working in the market.

To know more about why North America is leading the market growth in the Dental Implants And Prosthesis market, get a snapshot of the report Dental Implants And Prosthesis Market Trends

Dental Implants And Prosthesis Overview

Dental Implants and Prosthesis are solutions used to replace missing teeth and restore oral functionality and aesthetics. Dental Implants are titanium posts surgically inserted into the jawbone, serving as artificial tooth roots. They provide a strong foundation for attaching replacement teeth. Dental Prosthesis refers to artificial devices used to replace missing teeth and may include crowns, bridges, dentures, or implant-supported restorations.

DelveInsight Analysis: The dental implants and prosthesis market was estimated at USD 9.67 billion in 2023 and is projected to expand at a CAGR of 7.79% from 2024 to 2030, reaching approximately USD 15.16 billion by the end of the forecast period (2024-2030).

Dental Implants And Prosthesis Market Insights

Geographically, North America is projected to lead the dental implants and prosthesis market in 2023 and maintain its dominance throughout the forecast period. This trend is driven by the decline in oral health in the US, influenced by factors such as poor dietary habits and high intake of sugary foods and drinks. Additionally, the rising incidence of oral conditions like cavities and oral cancer, which often result in tooth loss, is fueling the demand for dental implants and prosthetics in the region between 2024 and 2030.

To read more about the latest highlights related to Dental Implants And Prosthesis, get a snapshot of the key highlights entailed in the Dental Implants And Prosthesis

https://www.delveinsight.com/report-store/dental-implants-and-prosthesis-market

Recent Developments in the Dental Implants And Prosthesis Market Report

• In January 2024, Dentsply Sirona, a prominent dental company in the US, introduced the Lucitone Digital Print Denture™ system for the Primeprint™ Solution. This system has received both FDA and CE approval for use in digital denture production using the Primeprint™ Solution.

• In January 2022, Renew, LLC and Western Dental & Orthodontics formed a strategic alliance to establish surgical centers in California and Texas, aiming to provide high-quality implant-supported removable anchored dentures.

• In June 2021, Neoss introduced NeossONE™, a distinctive solution within the Neoss® Implant System. It features a single prosthetic platform compatible across three implant lines, covering all implant diameters and abutments.

• Thus, owing to such developments in the market, rapid growth will be observed in the Dental Implants And Prosthesis market during the forecast period

Key Dental Implants And Prosthesis Companies In The Market

Some of the key market players operating in the Dental Implants And Prosthesis market include- Danaher Corporation, Straumann Holding AG, Dentsply Sirona, Zimmer Biomet, BioHorizons, Implant Direct Corporation, HIOSSEN, Inc., MEGA’GEN Implant Co. Ltd., ACE Surgical Supply Co., Inc., Bicon, LLC, Blue Sky Bio, Aseptico, Inc., Essential Dental Systems Inc., OSSTEM Implant Co., Ltd., DIO Corporation, Dental GmbH, 3M Company, DentiumUSA, Neoss Limited, Southern Implants, and others.

Which MedTech key players in the Dental Implants And Prosthesis market are set to emerge as the trendsetter explore @ Key Dental Implants And Prosthesis Companies

Analysis on the Dental Implants And Prosthesis Market Landscape

The dental implants and prosthesis market is experiencing notable expansion, primarily fueled by the rising occurrence of dental disorders, oral health complications, and periodontal conditions. Moreover, the aging population—more prone to such issues—is further boosting the demand for dental treatments and associated products. These elements are anticipated to significantly influence the market’s growth trajectory during the forecast period of 2024 to 2030.

Dentures offer several advantages, such as enhanced ability to chew and speak, support for facial structure, and prevention of facial sagging due to tooth loss. They also help maintain proper spacing among remaining teeth, reducing the risk of shifting. Furthermore, innovation in denture products is significantly driving market growth. For instance, in February 2024, Desktop Health introduced Flexcera Base Ultra+ resin, a 3D-printed material designed for full and partial removable dentures.

These versatile applications and advancements in denture technology are key contributors to the overall expansion of the dental implants and prosthesis market from 2024 to 2030.

Scope of the Dental Implants And Prosthesis Market Report

• Coverage: Global

• Study Period: 2021–2030

• Dental Implants And Prosthesis Market Segmentation By Implants: (Material [Titanium Implants and Zirconium Implants], Design [Tapered Dental Implants and Parallel-Walled Dental Implants

• Dental Implants And Prosthesis Market Segmentation By Type: [Endosteal Implants, Subperiosteal Implants, and Others

• Dental Implants And Prosthesis Market Segmentation By Prosthesis : (Dentures, Crown, Bridges, Veneer, Abutment, and Inlays & Onlays

• Dental Implants And Prosthesis Market Segmentation By End-User: Hospitals, Dental Clinics, and Others

• Dental Implants And Prosthesis Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of the World

• Key Dental Implants And Prosthesis Companies: Danaher Corporation, Straumann Holding AG, Dentsply Sirona, Zimmer Biomet, BioHorizons, Implant Direct Corporation, HIOSSEN, Inc., MEGA’GEN Implant Co. Ltd., ACE Surgical Supply Co., Inc., Bicon, LLC, Blue Sky Bio, Aseptico, Inc., Essential Dental Systems Inc., OSSTEM Implant Co., Ltd., DIO Corporation, Dental GmbH, 3M Company, DentiumUSA, Neoss Limited, Southern Implants, and others

• Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View

Interested in knowing how the Dental Implants And Prosthesis market will grow by 2030? Click to get a snapshot of the Dental Implants And Prosthesis Market Analysis

Table of Contents

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Global Dental Implants And Prosthesis Market to grow at a CAGR of 7.79% by 2030, Evaluates DelveInsight | Danaher Corporation, Straumann Holding AG, Dentsply Sirona, Zimmer Biomet, BioHorizons

“Congestive Heart Failure Treatment Market”

(Albany, USA) DelveInsight’s “Congestive Heart Failure Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of CHF, historical, and forecasted epidemiology as well as the CHF market trends in the US, EU4 (Germany, France, Italy, Spain), and the UK, and Japan.

The Congestive Heart Failure market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Congestive Heart Failure market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Congestive Heart Failure treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Congestive Heart Failure market.

Discover Key Insights into the Chronic Heart Failure Market with DelveInsight’s In-Depth Report @ Chronic Heart Failure Market Size

Key Takeaways from the Chronic Heart Failure Market Report

• In April 2025, AskBio Inc., announced a study of phase 2 study to evaluate the safety and efficacy of a single dose of AB-1002, administered via antegrade intracoronary artery infusion, in males and females age >18 years with non-ischemic cardiomyopathy and NYHA Class III symptoms of HF.
• In December 2024:- AstraZeneca- A Phase IIb Two-Cohort, Randomised, Placebo-controlled, Double-blind, Multi-centre, Dose-ranging Study of AZD5462 in Stable Patients With Chronic Heart Failure. The main purpose of this study is to evaluate the effect of AZD5462 on cardiac function in participants with chronic heart failure (HF). This is a Phase IIb randomized, double-blind, placebo-controlled, multi-center, dose-ranging study to evaluate the efficacy, safety, and pharmacokinetic (PK) of AZD5462 on top of standard of care in 2 cohorts of participants with HF: Cohort A, and Cohort B.
• In December 2024:- Regeneron Pharmaceuticals- A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of a Single Dose of REGN5381, an NPR1 Monoclonal Antibody Agonist, in Patients With Chronic Heart Failure With Reduced Ejection Fraction. This study is researching an experimental drug called REGN5381 (called “study drug”). The study is focused on patients with heart failure with reduced ejection fraction (ie, the heart is not functioning as well as it should).
• Driven by multiple factors, the number and distribution of reported cases of CHF have increased over time in the 7MM, among which the US contributed the major patient share.
• As per DelveInsight’s estimate, the total diagnosed prevalent cases of CHF in the 7MM were approximately 20,360,000 in 2023.
• In 2023, the percentage of diagnosed prevalence of males with heart failure in the US was 55%, and that for females was 45%.
• In the UK, among all the four NYHA Classes of heart failure, Class II accounted for around 45% of the total diagnosed prevalent heart failure cases in 2023.
• Among the EU4, the highest number of diagnosed prevalent cases of CHF were found in Germany, followed by France, and Spain, and the lowest number of diagnosed prevalent cases in Italy in 2023.
• In Japan, the age-specific dignosed prevalent cases of heart failure in 2023 accounted for approximately 4,444,000 (for age group more than 60 years), 634,900 (for age group 40-59 years), and 211,600 (for age group below 39 years).
• The leading Chronic Heart Failure Companies such as Novartis, Boehringer Ingelheim, Eli Lilly and Company, Bayer, Cytokinetics, BioCardia, Novo Nordisk, Mesoblast, and others.
• Promising Chronic Heart Failure Therapies such as Ertugliflozin, Metolazone, AZD5462, Vericiguat (Verquvo, BAY1021189), mRNA-0184, rhNRG-1, and others.

Stay ahead in the Chronic Heart Failure Therapeutics Market with DelveInsight’s Strategic Report @ Chronic Heart Failure Market Outlook

Chronic Heart Failure Epidemiology Segmentation in the 7MM

• Total Chronic Heart Failure Diagnosed Prevalent Cases
• Chronic Heart Failure Gender-Specific Cases
• Chronic Heart Failure Ejection fraction-specific cases
• Chronic Heart Failure NYHA class-specific cases
• Chronic Heart Failure Type-specific cases
• Chronic Heart Failure Age-specific cases

Download the report to understand which factors are driving Chronic Heart Failure epidemiology trends @ Chronic Heart Failure Prevalence

Marketed Congestive Heart Failure Drugs

• INJECTAFER (ferric carboxymaltose injection)/FERINJECT: American Regent, Vifor, and Daiichi Sankyo

INJECTAFER (ferric carboxymaltose injection) is indicated for the treatment of iron deficiency in adult patients with heart failure; Iron Deficiency Anemia (IDA) in adult and pediatric patients 1-year of age and older who have either intolerance to oral iron or unsatisfactory response to oral iron; and adult patients with IDA who have non-dialysis dependent chronic kidney disease. Its dosing for iron deficiency in adult patients with heart failure and NYHA class II/III is based on patient weight and hemoglobin level starting at a single 500mg dose up to two 1000mg doses separated by six weeks.

• INPEFA (sotagliflozin): Lexicon Pharmaceuticals and Viatris

INPEFA (sotagliflozin) is an oral inhibitor of two proteins responsible for glucose regulation known as SGLT2 and SGLT1. SGLT2 is responsible for glucose reabsorption by the kidney, and SGLT1 is responsible for glucose absorption in the gastrointestinal tract. In May 2023, Lexicon Pharmaceuticals announced that the US FDA had approved INPEFA (sotagliflozin) to reduce the risk of cardiovascular death, hHF, and uHF visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors. The broad label encompasses heart failure patients across the full range of LVEF, including HFpEF and HFrEF, and for patients with or without diabetes. The approval of INPEFA in heart failure indication, along with the breadth of the label, is a major milestone in Lexicon’s path to fulfilling its mission of pioneering medicines that transform patients’ lives.

Chronic Heart Failure Emerging Drugs

• Omecamtiv mecarbil: Cytokinetics

Omecamtiv mecarbil is a selective small-molecule cardiac myosin activator. It is designed to directly target the contractile mechanism or pumping function of the heart. By stimulating cardiac myosin, a protein responsible for converting chemical energy into the mechanical force that helps the heart contract, omecamtiv mecarbil may improve cardiac muscle performance. Preclinical research has shown that cardiac myosin activators increase cardiac contractility without affecting intracellular myocyte calcium concentrations or myocardial oxygen consumption. It has completed its Phase III for CHF and its Phase III for HFrEF is anticipated in the fourth quarter of 2024.

• KERENDIA (finerenone): Bayer

Finerenone is a nonsteroidal, selective Mineralocorticoid Receptor (MR) antagonist that has been shown to block the harmful effects of MR overactivation. MR overactivation contributes to Chronic Kidney Disease (CKD) progression and cardiovascular damage, which can be driven by metabolic, hemodynamic, or inflammatory and fibrotic factors. Finerenone is marketed as KERENDIA or, in some countries, as FIRIALTA, and approved for the treatment of adult patients associated with Type II Diabetes (T2D) in more than 90 countries worldwide, including in China, Europe, Japan, and the US. It has completed its Phase III trial for heart and left ventricular ejection fraction =40% and the company is anticipating the first submission of the drug by mid-2025.

Get In-Depth Knowledge on Chronic Heart Failure Market Trends and Forecasts with DelveInsight @ Chronic Heart Failure Treatment Market

Chronic Heart Failure Companies

Novartis, Boehringer Ingelheim, Eli Lilly and Company, Bayer, Cytokinetics, BioCardia, Novo Nordisk, Mesoblast, and others

Chronic Heart Failure Market Outlook

After a scarcity of sustainable new therapies for more than a decade, new classes of agents for the treatment of patients with CHF were approved by the US FDA – VERQUVO (vericiguat), ENTRESTO (sacubitril/valsartan), a combined Angiotensin Receptor-neprilysin Inhibitor (ARNI) and CORLANOR (ivabradine), a sinoatrial node modulator. Both drugs are recommended for use as part of a comprehensive medical therapy regimen. Recently approved INJECTAFER (ferric carboxymaltose injection)/FERINJECT by American Regent, Vifor, and Daiichi Sankyo and INPEFA (sotagliflozin) by Lexicon Pharmaceuticals and Viatris, in 2023 are the newest additions for treating heart failure. These drugs are indicated for the treatment of iron deficiency in adult patients with heart failure and to reduce the risk of cardiovascular death, hHF, and uHF visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors, respectively. VERQUVO is a stimulator of soluble guanylate cyclase.

Chronic Heart Failure Drugs Market

Currently, heart failure treatment depends on angiotensin-converting enzyme inhibitors, angiotensin receptor II blockers, beta-blockers, and diuretics. Other therapies, such as aldosterone antagonists, amiodarone, antiaggregants, anticoagulants, calcium antagonists, diuretics, and nitrates, are used to treat patients affected by heart failure. The majority of therapies are prescribed in combination, and beta-blockers are one of the most prescribed classes. Among the approved therapies, ENTRESTO is Novartis’ one of the most important drugs, and its revenue is expected to rise in the next years. At present, ENTRESTO leads the CHF market among the approved therapies.

Unlock Strategic Insights with DelveInsight’s Comprehensive Chronic Heart Failure Market Report @ Chronic Heart Failure Market Drivers and Barriers

Scope of the Chronic Heart Failure Market Report

• Coverage- 7MM
• Study Period- 2020-2034
• Chronic Heart Failure Companies- Novartis, Boehringer Ingelheim, Eli Lilly and Company, Bayer, Cytokinetics, BioCardia, Novo Nordisk, Mesoblast, and others.
• Chronic Heart Failure Therapies- Ertugliflozin, Metolazone, AZD5462, Vericiguat (Verquvo, BAY1021189), mRNA-0184, rhNRG-1, and others.
• Chronic Heart Failure Market Dynamics: Chronic Heart Failure Market Drivers and Barriers
• Chronic Heart Failure Unmet Needs, KOL’s views, Analyst’s views, Chronic Heart Failure Market Access and Reimbursement

Table of Content

1. Key Insights

2. Chronic Heart Failure Report Introduction

3. Chronic Heart Failure Executive Summary

4. Chronic Heart Failure Market Overview at a Glance

5. Chronic Heart Failure Key Events

6. Chronic Heart Failure Epidemiology and Market Forecast Methodology

7. Chronic Heart Failure Disease Background and Overview

9. Chronic Heart Failure Epidemiology and Patient Population

10. Patient Journey

11. Chronic Heart Failure Marketed Drugs

12. Chronic Heart Failure Emerging Drugs

13. Chronic Heart Failure: 7MM Analysis

14. Chronic Heart Failure Unmet needs

15. Chronic Heart Failure SWOT Analysis

16. Chronic Heart Failure KOL Views

17. Chronic Heart Failure Market Access and Reimbursement

18. Appendix

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/ats-conference-coverage

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Congestive Heart Failure Treatment Market 2034: EMA, PDMA, FDA Approvals, Medication, NICE Approvals, Clinical Trials, Revenue, Statistics, Therapies, Prevalence, Companies by DelveInsight